# Review Article

# The Role of Genetic Testing in Predicting Response to Heparin and Heparin-Induced Thrombocytopenia

**Nithesh Kumar Haridoss[1], Krishna Ravi[2]***

*From, [1]Department of Pharmacy Practice, JKKN College of Pharmacy, Namakkal, Tamil Nadu, India, [2]Associate Professor, Department of Pharmacy Practice, JKKN College of Pharmacy, Namakkal, Tamil Nadu, India.*

## ABSTRACT

Heparin remains one of the most widely used anticoagulants for the prevention and treatment of thromboembolic disorders; however, significant interindividual variability in therapeutic response and the risk of heparin-induced thrombocytopenia (HIT) continue to pose major clinical challenges. HIT is a serious immune-mediated adverse drug reaction characterized by thrombocytopenia and paradoxical thrombosis, often resulting in substantial morbidity and mortality if not identified promptly. Recent advances in pharmacogenomics and molecular diagnostics have highlighted the potential role of genetic testing in predicting heparin responsiveness and susceptibility to HIT. This review comprehensively examines the current evidence regarding genetic determinants influencing heparin pharmacodynamics, pharmacokinetics, and immune-mediated adverse reactions. Particular emphasis is placed on polymorphisms in genes such as FCGR2A, CYP2C9, VKORC1, HLA-DR, HLA-DQ, TDAG8, and PF4, which have been associated with altered anticoagulant response, platelet activation, and thrombotic risk. The review also discusses the molecular mechanisms underlying HIT, including PF4-heparin complex formation, antibody-mediated platelet activation, and thrombin generation. Furthermore, contemporary genetic testing approaches, including genome-wide association studies (GWAS), candidate gene analysis, and next-generation sequencing (NGS), are evaluated for their clinical applicability in risk stratification and individualized therapy. The integration of genetic profiling into heparin therapy may facilitate personalized anticoagulation strategies, improve patient safety, reduce adverse outcomes, and support precision medicine approaches in thrombosis management. Despite promising advancements, challenges related to clinical validation, cost-effectiveness, and implementation in routine healthcare settings remain. Future large-scale studies and standardized testing algorithms are essential to establish the clinical utility of pharmacogenomic-guided heparin therapy and HIT prevention.

***Key words:*** Heparin-induced thrombocytopenia; Pharmacogenomics; Genetic testing; Heparin therapy; Personalized medicine; Anticoagulant therapy; Precision medicine.

Heparin, a widely used anticoagulant, plays a crucial role in the management of various cardiovascular conditions in clinical practice. Its efficacy and safety are paramount, as it is administered to millions of patients worldwide [1,2]. Understanding patient response to heparin is vital, as it directly impacts treatment outcomes and patient safety. In India, where cardiovascular diseases are a significant public health burden, the accurate prediction of heparin response is essential to ensure optimal treatment and minimize adverse reactions.

Heparin-induced thrombocytopenia (HIT) is a life-threatening, immune-mediated adverse reaction to heparin anticoagulants. Characterized by thrombocytopenia and thrombosis, HIT can lead to catastrophic complications, including stroke, myocardial infarction, and limb loss [3]. The unpredictable nature of HIT makes it challenging to diagnose and manage effectively, emphasizing the need for predictive biomarkers to identify at-risk patients [1-4].

Genetic testing has the potential to revolutionize the prediction of heparin response and the development of HIT. By identifying genetic variations associated with altered heparin response and HIT risk, clinicians can tailor treatment strategies to individual patients, reducing the likelihood of adverse reactions. This approach can significantly improve patient outcomes and healthcare delivery in India, where the burden of cardiovascular diseases is substantial [5].

This review aims to discuss the role of genetic testing in predicting response to heparin and the development of HIT. It will explore the current understanding of genetic variations associated with heparin response and HIT, highlighting the potential of genetic testing to shift clinical practice paradigms

**Access this article online**

Quick Response Code

Received – 10th October 2024
Initial Review – 18th October 2024
Accepted – 28th October 2024

**Correspondence to:** Dr. Krishna Ravi, Department of Pharmacy Practice, JKKN College of Pharmacy, Namakkal, Tamil Nadu, India
**Email:** drkrishnaravi.7kr@gmail.com

from early detection and treatment to prevention.

## 2. Heparin Pharmacology and Mechanism of Action

### 2.1 Mechanism of Action

Heparin is a potent anticoagulant due to its ability to potentiate the action of antithrombin, a major inhibitor of the coagulation cascade. Heparin binds to antithrombin through a high-affinity pentasaccharide sequence, which is present in about a third of heparin molecules. This binding induces a conformational change in antithrombin, significantly enhancing its ability to inactivate thrombin and activated factor X (factor Xa) [1].

For the inhibition of thrombin, heparin must bind to both the coagulation enzyme and antithrombin, whereas binding to the enzyme is not required for the inhibition of factor Xa. Heparin molecules with fewer than 18 saccharides lack the chain length to bridge between thrombin and antithrombin, and therefore, are unable to inhibit thrombin. In contrast, very small heparin fragments containing the pentasaccharide sequence can inhibit factor Xa via antithrombin [2].

By inactivating thrombin, heparin not only prevents fibrin formation but also inhibits thrombin-induced activation of platelets and factors V and VIII, further contributing to its anticoagulant effects [3].

### 2.2 Pharmacokinetics and Pharmacodynamics

The pharmacokinetics and pharmacodynamics of heparin are complex and influenced by various factors. Heparin exhibits variable anticoagulant responses due to its propensity to bind to positively charged proteins and surfaces. This AT-independent binding to plasma proteins, proteins released from platelets, and endothelial cells results in a variable anticoagulant response and the phenomenon of heparin resistance [1-3].

Heparin's pharmacokinetics are also affected by AT-independent clearance mechanisms, such as binding to macrophages and endothelial cells, leading to dose-dependent clearance. Additionally, heparin is unable to inactivate factor Xa in the prothrombinase complex or thrombin bound to fibrin or subendothelial surfaces, further contributing to its pharmacodynamic limitations [1-3].

To address the variable anticoagulant response, it is standard practice to adjust the dose of heparin and monitor its effect by measuring the activated partial thromboplastin time (APTT) or, in the case of very high doses, the activated clotting time (ACT) [1-3].

### 2.3 Non-anticoagulant Properties of Heparin

In addition to its well-established anticoagulant activities, heparin has been recognized to possess various non anticoagulant properties, including antiviral, anti-inflammatory, and antimetastatic actions. These activities are often independent of heparin's anticoagulant effects, although the underlying mechanisms are not yet fully elucidated [4-6].

The diverse pharmacological properties of heparin have led to its exploration and development for a wide range of clinical applications beyond anticoagulation, such as the treatment of COVID-19 and other inflammatory conditions. This expanding understanding of heparin's multifaceted actions underscores its therapeutic potential in various clinical settings [7,8].

## 3. Factors Influencing an Individual's Response to Heparin

### 3.1 Genetic Variations

Genetic variations play a significant role in influencing an individual's response to heparin. Studies have shown that genetic factors can impact the pharmacokinetics and pharmacodynamics of heparin, leading to variability in drug response among patients [9]. For instance, genetic polymorphisms in genes encoding enzymes involved in heparin metabolism, such as CYP2C9 and VKORC1, have been associated with altered heparin response and the risk of adverse reactions like heparin-induced thrombocytopenia (HIT) [10].

Moreover, the presence of specific genetic variants can affect the binding affinity of heparin to antithrombin, influencing the anticoagulant activity of heparin in individuals [11]. Variations in genes related to platelet factor 4 (PF4) and heparin antibodies have also been linked to the development of HIT, highlighting the genetic basis for adverse reactions to heparin therapy [12].

Understanding an individual's genetic profile can provide valuable insights into their likelihood of experiencing adverse reactions to heparin and guide personalized treatment strategies to optimize therapeutic outcomes and minimize risks associated with heparin therapy [13].

### 3.2 Comorbidities

Comorbidities, such as renal impairment, liver dysfunction, and cardiovascular diseases, can significantly impact an individual's response to heparin. Patients with renal insufficiency may exhibit altered clearance of heparin, leading to prolonged drug effects and an increased risk of bleeding complications [14]. Similarly, individuals with liver disease may have impaired synthesis of clotting factors, affecting the overall anticoagulant response to heparin therapy [8].

Furthermore, patients with underlying cardiovascular conditions, such as atrial fibrillation or deep vein thrombosis, may require different dosing regimens or monitoring strategies to ensure optimal anticoagulation with heparin [15]. The presence of comorbidities can complicate the management of heparin therapy and necessitate individualized treatment approaches tailored to the patient's specific health conditions [14].

### 3.3 Drug Interactions

Drug interactions can also influence an individual's response to heparin therapy. Concomitant use of medications that affect the coagulation cascade, such as antiplatelet agents or nonsteroidal anti-inflammatory drugs (NSAIDs), can potentiate the anticoagulant effects of heparin and increase the risk of bleeding complications [16]. Conversely, drugs that induce hepatic enzymes, like rifampicin or phenytoin, may reduce the efficacy of heparin by accelerating its metabolism and clearance from the body [2].

Healthcare providers need to consider potential drug interactions when prescribing heparin to ensure safe and effective treatment outcomes for patients [17]. Monitoring for adverse effects and adjusting treatment regimens based on individual factors, including genetic variations, comorbidities, and concomitant medications, is crucial in optimizing the therapeutic benefits of heparin while minimizing the risks associated with its use [17].

## 4. Genetic Factors Influencing Heparin Response

### 4.1 FCGR2A H131R Polymorphism and Heparin-Induced Thrombocytopenia

The FCGR2A H131R polymorphism has been consistently identified as a key genetic marker associated with an increased risk of heparin-induced thrombocytopenia (HIT) [18]. This polymorphism, located in the Fc receptor gamma IIa gene, plays a crucial role in the pathogenesis of HIT by affecting the binding affinity of the receptor to the Fc region of immunoglobulins [19].

#### 4.1.1 Role of FcγRIIA in HIT Pathogenesis

FcγRIIA, the only Fc receptor present on platelets, mediates the interaction between platelets and antibodies. When stimulated, FcγRIIA activates platelets, leading to the mass activation and consequent widespread thrombosis observed in HIT [18]. The H131R polymorphism in FcγRIIA alters the binding affinity of the receptor to IgG antibodies, potentially contributing to the increased risk of thrombosis in individuals with this genetic variant [19].

#### 4.1.2 Mechanism of Action

The H131R polymorphism in FcγRIIA results in the substitution of histidine (H) with arginine (R) at position 131 of the receptor. This amino acid change affects the binding affinity of the receptor to the Fc region of IgG antibodies [9]. Individuals homozygous for the R allele (RR genotype) have been shown to have more efficient activation of platelets by IgG antibodies compared to those with the HH or HR genotypes [19].

#### 4.1.3 Potential Applications in Risk Stratification

Identifying individuals with the FCGR2A H131R polymorphism may aid in risk stratification for HIT development and guide treatment decisions [9]. Patients with the RR genotype may benefit from closer monitoring or alternative anticoagulation strategies to mitigate the risk of HIT-related thrombotic events[18]. Incorporating genetic testing for the FCGR2A H131R polymorphism into clinical practice could help optimize patient management and improve outcomes in heparin-treated individuals [19].

### 4.2 CYP2C9 and VKORC1 Polymorphisms and Heparin Response

#### 4.2.1 Role of CYP2C9 Polymorphisms

The CYP2C9 gene encodes the cytochrome P450 2C9 enzyme, which is responsible for the metabolism of heparin. Genetic polymorphisms in the CYP2C9 gene can significantly impact an individual's response to heparin therapy [20].

The most well-studied CYP2C9 polymorphisms are the *2 and 3 alleles, which result in decreased enzyme activity. Individuals with the CYP2C92 or 3 alleles may exhibit altered heparin clearance, leading to an increased risk of adverse events, such as bleeding complications[21]. The CYP2C93 allele, in particular, has been associated with a more pronounced effect on heparin metabolism, with carriers of the *3/*3 genotype requiring significantly lower heparin doses to achieve the desired anticoagulant effect [9].

In addition to the well-characterized *2 and *3 alleles, other less common CYP2C9 variants have also been identified, such as the *46 allele, which has been shown to impair the enzymatic activity of CYP2C9 in vitro. The clinical significance of these rare CYP2C9 variants in the context of heparin response is an area that requires further investigation [11].

#### 4.2.2 Role of VKORC1 Polymorphisms

The VKORC1 gene encodes the vitamin K epoxide reductase complex subunit 1, which is a key enzyme in the vitamin K cycle and plays a crucial role in the regulation of blood coagulation. Genetic variations in the VKORC1 gene can influence an individual's response to heparin, as this enzyme is involved in the activation of vitamin K-dependent clotting factors [20].

The VKORC1 -1639G>A polymorphism is one of the most well-studied variants in the context of heparin response. Individuals with the VKORC1 -1639AA genotype have been shown to require lower heparin doses to achieve the desired anticoagulant effect, as the A allele is associated with reduced enzyme activity and, consequently, a more sensitive response to heparin [21].

The combined effects of CYP2C9 and VKORC1 polymorphisms can have a significant impact on an individual's heparin response. Patients with genetic variants in both genes may require more personalized dosing strategies to ensure the safe and effective use of heparin in clinical practice [11].

### 4.3 HLA-DR and HLA-DQ Polymorphisms and Heparin-Induced Thrombocytopenia

#### 4.3.1 Role of HLA-DR Polymorphisms

The HLA-DR region within the major histocompatibility complex (MHC) has emerged as a key genetic factor influencing the risk of heparin-induced thrombocytopenia (HIT) [22]. Specific HLA-DR alleles and polymorphisms have been associated with the development of HIT and the production of platelet factor 4 (PF4)/heparin antibodies, which are central to the pathogenesis of this condition [22].

The HLA-DRA gene, in particular, has been identified as a potential genetic predictor of HIT [23]. A genome-wide association study (GWAS) found that single-nucleotide polymorphisms (SNPs) near the HLA-DRA gene were significantly associated with the risk of developing HIT[23]. These HLA-DRA variants appear to influence HIT pathogenesis independently of classical HLA-DR alleles, suggesting a unique role for this gene in the immune response to heparin [24].

Furthermore, the HLA-DR3 serotype, which is associated with the HLA-DRB103:01 allele, has been linked to the formation of PF4/heparin antibodies and the development of thrombotic thrombocytopenic purpura, a condition with similarities to HIT [23]. This highlights the potential involvement of specific HLA-DR alleles in the immune-mediated mechanisms underlying HIT [9].

#### 4.3.2 Role of HLA-DQ Polymorphisms

In addition to HLA-DR, genetic variations in the HLA-DQ region have also been implicated in the risk of HIT [22]. The HLA-DQ molecules, encoded by the HLA-DQA1 and HLA-DQB1genes, play a crucial role in the presentation of antigenic peptides to T cells, which is a key step in the development of the immune response underlying HIT [23].

While the specific HLA-DQ alleles associated with HIT have not been as extensively studied as HLA-DR, some evidence suggests that certain HLA-DQ genotypes may confer an increased susceptibility to the development of HIT [9]. Further research is needed to elucidate the precise role of HLA-DQ polymorphisms in the pathogenesis of this condition [24].

### 4.4 Other Genetic Variants and Heparin Response in HIT

#### 4.4.1 Role of T-Cell Death-Associated Gene 8 (TDAG8) Variants

Genetic variants in the T-Cell Death-Associated Gene 8 (TDAG8) have been implicated in altered heparin response and the risk of heparin-induced thrombocytopenia (HIT) [22].TDAG8, also known as GPR65, is a G protein-coupled receptor involved in various cellular processes, including immune responses and inflammation [22].

Studies have identified associations between TDAG8 variants and HIT risk, suggesting a potential role for this gene in the pathogenesis of the condition [25]. The exact mechanisms by which TDAG8 variants influence heparin response and the development of HIT remain to be fully elucidated [26]. Further research is needed to explore the functional implications of TDAG8 polymorphisms in HIT pathophysiology [26].

#### 4.4.2 Role of Platelet Factor 4 (PF4) Gene Variants

Variants in the Platelet Factor 4 (PF4) gene have also been linked to altered heparin response and the risk of HIT. PF4 is a small cytokine released from platelets upon activation, and it forms complexes with heparin that can trigger an immune response leading to HIT [22].

Genetic variations in the PF4 gene may influence the production of PF4/heparin antibodies, which are central to the pathogenesis of HIT [25]. These variants could potentially impact the immune recognition of PF4/heparin complexes and the subsequent antibody response in individuals exposed to heparin therapy [26].

## 5. Clinical Implications of Genetic Factors in Guiding Heparin Dosing and Monitoring

### 5.1 Role of CYP2C9 and VKORC1 in Heparin Dosing

The genetic variations in the CYP2C9 and VKORC1 genes have significant implications for heparin dosing and monitoring. CYP2C9 is responsible for the metabolism of heparin, and genetic polymorphisms in this gene can affect the clearance of the drug. VKORC1, on the other hand, is involved in the regulation of vitamin K-dependent clotting factors, and genetic variations in this gene can influence the anticoagulant response to heparin [27].

Studies have shown that individuals with specific genetic variants in CYP2C9 and VKORC1 may require different dosing regimens or monitoring strategies to achieve optimal anticoagulation. For instance, individuals with the CYP2C9*2 or *3 alleles may require lower heparin doses to achieve the desired anticoagulant effect due to their impaired enzyme activity [28,29].

### 5.2 Role of FCGR2A in Heparin-Induced Thrombocytopenia

The FCGR2A gene, which encodes the Fc receptor gamma IIa (FcγRIIA), plays a crucial role in the pathogenesis of heparin-induced thrombocytopenia (HIT). Genetic variations in this gene, such as the H131R polymorphism, have been associated with an increased risk of HIT-related thrombosis [11],[30,31].

Understanding the role of FCGR2A in HIT can help guide the management of patients receiving heparin therapy. For instance, patients with the H131R polymorphism may require closer monitoring or alternative anticoagulant therapies to

minimize the risk of HIT-related thrombotic complications [31,32].

### 5.3 Role of HLA-DR and HLA-DQ in Heparin Response

Genetic variations in the HLA-DR and HLA-DQ genes have been associated with altered heparin response and the risk of HIT. These genes are involved in the presentation of antigenic peptides to T cells, a crucial step in the immune response underlying HIT [33-35].

Understanding the role of HLA-DR and HLA-DQ in heparin response can help guide the management of patients receiving heparin therapy. For instance, patients with specific HLA-DR or HLA-DQ alleles may require different dosing regimens or monitoring strategies to achieve optimal anticoagulation [33-35].

## 6. Heparin-Induced Thrombocytopenia (HIT)

### 6.1 Immune-Mediated Mechanisms in Heparin-Induced Thrombocytopenia

#### 6.1.1 Formation of PF4-Heparin Complexes

The pathophysiology of heparin-induced thrombocytopenia (HIT) is initiated by the binding of heparin to platelet factor 4 (PF4), forming stable ultralarge complexes (ULCs) composed of multiple PF4 tetramers arranged in a lattice structure. These ULCs, with a molecular weight exceeding 670 kDa, serve as the antigenic targets for the immune response in HIT [36-38].

#### 6.1.2 Anti-PF4/Heparin Antibody Production

The PF4-heparin complexes trigger an immune response, leading to the production of antibodies targeting these complexes. These antibodies, predominantly of the IgG class, can be detected in the plasma of over 90% of patients clinically diagnosed with HIT. However, the presence of these antibodies alone does not necessarily lead to the development of HIT, as they can also be found in patients who have been exposed to heparin without developing the condition [15], [39,40].

#### 6.1.3 Platelet Activation by PF4/Heparin Antibodies

The binding of anti-PF4/heparin antibodies to the PF4-heparin complexes on the platelet surface is a crucial step in the pathogenesis of HIT. This binding activates platelets through cross-linking of the FcγRIIA receptor, leading to the release and expression of PF4. The activated platelets release procoagulant microparticles, contributing to the prothrombotic state observed in HIT [15], [39], [41,42].

#### 6.1.4 Thrombin Generation and Endothelial Activation

The activation of platelets and the release of PF4 create a positive feedback loop, further propagating platelet activation and thrombin generation. Activated monocytes and endothelial cells also contribute to thrombin generation through the expression of tissue factor and the release of tissue factor-bearing microparticles. Endothelial activation leads to the secretion of von Willebrand factor, on which PF4 can bind, creating an Fc-rich surface that promotes further platelet activation [43-46].

#### 6.1.5 Neutrophil Activation and NETosis

In addition to platelets and monocytes, neutrophils also play a role in the prothrombotic state of HIT. Activated neutrophils undergo NETosis, releasing neutrophil extracellular traps (NETs) that provide a scaffold for platelet adhesion and thrombin generation [47-49]. The Fc-rich surfaces created by NETs further activate platelets, contributing to the thrombotic complications observed in HIT [50].

#### 6.1.6 Delayed-Onset and Persistent HIT

In some cases, anti-PF4/heparin antibodies can recognize PF4 bound to platelet chondroitin sulfate, activating platelets even in the absence of heparin. This mechanism explains delayed-onset HIT, where thrombocytopenia and thrombosis occur after heparin exposure has ceased, as well as persistent HIT, where recovery may take several weeks due to the sustained immune response and platelet activation [51-54] (Figure 1).




**Figure 1: Pathophysiology of Heparin-Induced Thrombocytopenia (HIT): Immunologic and Thrombotic Mechanisms**

### 7. Clinical Presentation of HIT

The clinical presentation of heparin-induced thrombocytopenia (HIT) can be variable, but the most common feature is asymptomatic thrombocytopenia[53]. The platelet count typically falls by 30-50% from baseline, with a nadir usually remaining above 20 x 10^9/L [15]. Thrombocytopenia tends to occur between days 5-10 of heparin exposure, although it can occur within 24 hours in patients with recent prior heparin exposure (within the past 100 days) [55].

In addition to thrombocytopenia, HIT may present with skin lesions at heparin injection sites or acute systemic reactions (e.g., chills, fever, dyspnea, chest pain) after administration of an intravenous bolus of heparin[53]. Unlike other forms of thrombocytopenia, significant spontaneous bleeding is rare in HIT. Instead, the most dreaded complication is thrombosis, which may be limb- or life-threatening [55]. New thromboembolism is the presenting feature in approximately half of cases and may precede the onset of thrombocytopenia [15].

### 8. Diagnosis of Heparin-Induced Thrombocytopenia

The diagnosis of heparin-induced thrombocytopenia (HIT) is a clinical challenge that requires a combination of clinical findings, laboratory tests, and risk assessment. Prompt recognition and diagnosis of HIT are crucial, as delayed treatment can lead to devastating thrombotic complications.

#### 8.1 Clinical Presentation and 4Ts Score

The main clinical presentation of HIT is thrombocytopenia, which typically occurs between days 5-10 of heparin exposure. The platelet count usually falls by 30-50% from baseline, with a nadir often remaining above 20 × 10^9/L. However, thrombocytopenia can occur within 24 hours in patients with recent prior heparin exposure (within the past 100 days) [56,57].

The pretest probability of HIT can be estimated using the 4Ts scoring system, which takes into account the timing of thrombocytopenia, degree of platelet count fall, presence of thrombosis, and likelihood of other causes of thrombocytopenia. A high or intermediate 4Ts score warrants further investigation with immunologic assays to detect HIT antibodies [56],[58,59].

#### 8.2 Immunologic Assays

Immunologic assays, such as enzyme-linked immunosorbent assays (ELISAs), are used to detect antibodies against the heparin-platelet factor 4 (PF4) complex. These assays have high sensitivity but lower specificity, meaning that a positive result indicates the presence of HIT antibodies but does not necessarily confirm the diagnosis [60].

#### 8.3 Functional Assays

If the immunologic assay is positive, a functional assay, such as the serotonin release assay (SRA) or heparin-induced platelet activation (HIPA) test, is recommended for confirmation. These assays measure the ability of the patient's serum to activate platelets in the presence of heparin and have higher specificity for detecting clinically relevant HIT antibodies [61,62].

### 9. Management of Heparin-Induced Thrombocytopenia (HIT)

The management of heparin-induced thrombocytopenia (HIT) is a critical aspect of patient care, requiring prompt recognition and appropriate therapeutic interventions to prevent life-threatening thrombotic complications.

#### 9.1 Immediate Discontinuation of Heparin

The cornerstone of HIT management is the immediate discontinuation of all heparin products, including heparin flushes of intravenous catheters. This step is crucial to prevent further exposure to heparin and mitigate the risk of exacerbating the immune-mediated response that underlies HIT [63,64].

#### 9.2 Initiation of Alternative Anticoagulation

Following the discontinuation of heparin, patients with HIT should be promptly started on an alternative anticoagulant to prevent and treat thrombotic complications associated with the condition. Direct thrombin inhibitors, such as argatroban and bivalirudin, are commonly used as first-line agents in HIT management due to their efficacy in inhibiting thrombin generation without relying on antithrombin III [65,66].

#### 9.3 Factor Xa Inhibitors as Alternative Agents

In addition to direct thrombin inhibitors, factor Xa inhibitors, such as fondaparinux, have emerged as valuable alternatives for the management of HIT-related thrombosis. Fondaparinux, although not FDA-approved for HIT, is considered safe and effective, making it a recommended agent according to guidelines from the American Society of Hematology (ASH) [66,67].

#### 9.4 Transition to Long-Term Anticoagulation

Once the platelet count has recovered and the patient is no longer at immediate risk of HIT-related thrombosis, long-term anticoagulation with warfarin may be initiated for continued anticoagulant therapy. Warfarin is typically started at low doses and should be overlapped with a direct thrombin inhibitor for at least 5 days to ensure adequate anticoagulation during the transition period.

#### 9.5 Close Monitoring and Vigilance

Close monitoring of the platelet count and vigilance for signs of thrombosis are essential components of HIT management to ensure the timely detection of any thrombotic events and the effectiveness of anticoagulant therapy. Regular follow-up

assessments and adherence to monitoring protocols are crucial to optimizing patient outcomes and minimizing the risk of recurrent thrombotic complications associated with HIT.

## 10. Genetic Testing for Heparin Response and Heparin-Induced Thrombocytopenia

The field of genetic testing has made significant strides in understanding the genetic factors underlying heparin response and the development of heparin-induced thrombocytopenia (HIT). Researchers have employed various genetic testing technologies to identify genetic markers associated with altered heparin response and the risk of HIT.

### 10.1 Genome-Wide Association Studies (GWAS)

Genome-wide association studies have been instrumental in identifying genetic variants associated with HIT [68]. These studies scan the entire genome for genetic variations that are linked to the condition [69]. GWAS have identified several genetic markers, including variants in the FCGR2A, TDAG8, HLA-DR, and HLA-DQ genes, that are associated with an increased risk of developing HIT [68,69].

### 10.2 Candidate Gene Approach

The candidate gene approach focuses on investigating genetic variants in specific genes known to be involved in the pathophysiology of HIT. This approach has been used to study the FCGR2A gene, which encodes the Fc receptor gamma IIa and plays a crucial role in the immune response underlying HIT [70-72].

### 10.3 Next-Generation Sequencing (NGS)

Next-generation sequencing technologies have enabled the simultaneous analysis of multiple genes and genetic variants associated with heparin response and HIT. NGS has been used to identify genetic variants in genes such as FCGR2A, TDAG8, HLA-DR, and HLA-DQ, which have been linked to the risk of developing HIT [73],[74].

### 10.4 Sensitivity and Specificity of Genetic Tests

The sensitivity and specificity of genetic tests for predicting heparin response and HIT risk vary depending on the specific genetic markers being evaluated. The FCGR2A H131R polymorphism, for instance, has been consistently associated with an increased risk of HIT-related thrombosis, with studies reporting a higher sensitivity and specificity for this genetic marker [75,76].

In contrast, the genetic associations with HIT risk for other markers, such as those in the TDAG8 and HLA-DR/DQ genes, have been less consistent, with some studies reporting moderate to high sensitivity but lower specificity [76,77]. This highlights the need for further research to validate the clinical utility of these genetic markers [75,76].

### 10.5 Clinical Utility and Challenges

The clinical utility of genetic testing in the context of heparin response and HIT is an area of active research and development. Genetic testing has the potential to identify individuals at high risk of developing HIT, allowing for targeted interventions and personalized treatment strategies.

However, several challenges and limitations exist in the integration of genetic testing into clinical practice. These include the need for larger and more diverse study populations, the development of standardized testing protocols, and the interpretation of genetic test results in the context of other clinical and laboratory findings.

Additionally, the cost-effectiveness of genetic testing and the ethical considerations surrounding the use of genetic information in healthcare settings must be carefully evaluated to ensure the responsible and equitable implementation of these technologies.

## 11. Clinical Implications and Future Perspectives

The incorporation of genetic testing into the management of patients receiving heparin holds significant clinical benefits and the potential to transform the approach to heparin-induced thrombocytopenia (HIT) prevention and treatment.

### 11.1 Personalized Dosing and Risk Stratification

Genetic testing can help identify individuals with genetic variants associated with altered heparin response and an increased risk of HIT. By understanding a patient's genetic profile, clinicians can tailor heparin dosing regimens to optimize anticoagulation and minimize the risk of adverse events. Patients with high-risk genetic variants, such as the FCGR2A H131R polymorphism, may require closer monitoring or the use of alternative anticoagulants to prevent the development of HIT-related thrombotic complications [78,79].

### 11.2 Prevention of Adverse Events

The ability to identify high-risk individuals through genetic testing can enable a shift in clinical practice from early detection and treatment to prevention of HIT. By avoiding heparin exposure in patients with known genetic susceptibility, healthcare providers can potentially prevent the development of this life-threatening adverse reaction, improving patient outcomes and reducing the burden on the healthcare system [78].

### 11.3 Integration of Genetic Data with Clinical Factors

The integration of genetic data with other clinical factors, such as patient demographics, comorbidities, and drug interactions, can provide a more comprehensive risk assessment for HIT. This holistic approach can help clinicians make informed decisions regarding the use of heparin and the implementation of appropriate preventive strategies [9].

### 11.4 Development of Novel Genetic Markers

While current research has identified several genetic markers associated with HIT risk, such as variants in the FCGR2A, TDAG8, HLA-DR, and HLA-DQ genes, there is a need for the discovery of additional genetic biomarkers. Ongoing genome-wide association studies (GWAS) and advanced sequencing technologies may uncover novel genetic variants that can further enhance the predictive power of genetic testing for HIT [79].

### 11.5 Optimization of Genetic Testing Algorithms

To effectively integrate genetic testing into clinical practice, the development of standardized testing protocols and decision-making algorithms is crucial. These algorithms should incorporate the interpretation of genetic test results, the integration of genetic data with other clinical factors, and the implementation of personalized management strategies based on the patient's risk profile [79].

## CONCLUSION

The incorporation of genetic testing into the management of patients receiving heparin holds immense promise in improving clinical outcomes and reducing the burden of heparin-induced thrombocytopenia (HIT). By identifying individuals with genetic variants associated with an increased risk of HIT, clinicians can implement personalized dosing strategies, optimize anticoagulation management, and prevent the development of this life-threatening adverse reaction. The ability to stratify patients based on their genetic risk profile can enable a shift in clinical practice from early detection and treatment to proactive prevention, potentially reducing the incidence of HIT-related thrombotic complications and improving overall patient safety.

While current research has identified several genetic markers, such as variants in the FCGR2A, TDAG8, HLA-DR, and HLA-DQ genes, ongoing studies aim to uncover additional genetic biomarkers and develop standardized testing protocols that can be seamlessly integrated into routine clinical practice. As the field of pharmacogenomics continues to evolve, the integration of genetic testing into the management of heparin therapy holds the potential to transform the way clinicians approach the prevention and treatment of HIT, ultimately leading to better patient outcomes and more efficient healthcare delivery.

## REFERENCE


1. Mousa SA, Zhang F, Aljada A, et al. Pharmacokinetics and Pharmacodynamics of Oral Heparin Solid Dosage Form in Healthy Human Subjects. J Clin Pharmacol. 2007;47(12):1508-1520.
2. Drugbank. Heparin. go.drugbank.com. Published 2018. https://go.drugbank.com/drugs/DB01109
3. Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 1992 May;22(5):359-74.
4. Thachil J. Clinical differentiation of anticoagulant and non-anticoagulant properties of heparin. J Thromb Haemost. 2020;18(9):2424-2425.
5. Beurskens DMH, Huckriede JP, Schrijver R, Hemker HC, Reutelingsperger CP, Nicolaes GAF. The Anticoagulant and Nonanticoagulant Properties of Heparin. Thromb Haemost. 2020;120(10):1371-1383.
6. Shute JK. Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease. Pharmaceuticals. 2023;16(4):584.
7. Mulloy B. The non-anticoagulant promise of heparin and its mimetics. Curr Opin Pharmacol. 2019;46(1):50-54.
8. Buijsers B, Yanginlar C, Maciej-Hulme ML, de Mast Q, van der Vlag J. Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients. EBioMedicine. 2020;59:102969.
9. Karnes JH. Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know? Pharmacogenomics. 2018;19(18):1413-1422.
10. Giles J, Steiner HE, Rollin J, et al. Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia. Blood Adv. 2022;6(14).
11. Miller E, Norwood C, Giles JB, et al. PharmGKB summary. Pharmacogenet Genomics. 2022;32(3).
12. Hikino K, Koido M, Ide K, et al. Individual variation in unfractionated heparin dosing after pediatric cardiac surgery. Sci Rep. 2020;10(1).
13. Manlhiot C, Mital S, Gruenwald CE, et al. Abstract 18481: Genetic Polymorphisms Associated with Response to Intraoperative Heparin Anticoagulation and Thrombosis Risk in Pediatric Patients Undergoing Cardiac Surgery. Circulation. 2012;126(suppl_21).
14. Darok M, Daly A, Walter V, Krawiec C. Association of medical comorbidities in obese subjects diagnosed with heparin-induced thrombocytopenia. SAGE Open Med. 2024;12:1-8.
15. Arepally GM, Padmanabhan A. Heparin-Induced Thrombocytopenia. Arterioscler Thromb Vasc Biol. 2020;41(1).
16. Harder S, Thürmann P. Clinically Important Drug Interactions with Anticoagulants. Clin Pharmacokinet. 1996;30(6):416-444.
17. Medscape. Heparin dosing, indications, interactions, adverse effects, and more. Medscape.com. Published September 28, 2019. https://reference.medscape.com/drug/calciparine-monoparin-heparin-342169
18. Rollin J, Pouplard C, Leroux D, et al. Influence of FcγRIIA H131R Polymorphism on the Risk of Thrombosis in HIT and Variable Effect of Normal IgG on Platelet Activation. Blood. 2014;124(21):234-234.
19. Christos Kroupis, Theodorou M, Kounavi M, et al. Development of a real-time PCR detection method for a FCGR2A polymorphism in the LightCycler and application in the heparin-induced thrombocytopenia syndrome. Clin Biochem. 2009;42(16-17):1685-1693.
20. Miklosz J, Kalaska B, Mogielnicki A. Pharmacogenetic considerations of anticoagulant medication. J Physiol Pharmacol. 2018 Aug;69(4).
21. Dean L. Warfarin Therapy and VKORC1 and CYP Genotype. PubMed. Published 2012. https://www.ncbi.nlm.nih.gov/books/NBK84174/
22. Karnes JH, Cronin RM, Rollin J, et al. A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record. Thromb Haemost. 2015;113(04):772-781.
23. Tizaoui K. Multiple sclerosis genetics: Results from meta-analyses of candidate-gene association studies. Cytokine. 2018;106:154-164.
24. Ebringer A. Molecular Mimicry. Elsevier eBooks. Published online January 1, 1998:1736-1742.
25. Cross B, Turner RM, J. Eunice Zhang, Munir Pirmohamed. Being precise with anticoagulation to reduce adverse drug reactions: are we there yet? Pharmacogenomics J. 2024;24(2).
26. Gowthami Arepally, Mortimer Poncz, Cines DB. Autoantibodies In Heparin-Induced Thrombocytopenia. Elsevier eBooks: 511-519.

27. Patsopoulos N, Belknap S, O'Rourke D, et al. Effect of Genetic Variants, Especially CYP2C9 and VKORC1, on the Pharmacology of Warfarin. Semin Thromb Hemost. 2012;38(08):893-904.
28. Natarajan S, Ponde CK, Rajani RM, et al. Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients. Pharmacol Rep. 2013;65(5):1375-1382.
29. Dansette PM, Danièle Werck-Reichhart. Cytochromes P450: Drug Metabolism, Bioactivation and Biodiversity 2.0. MDPI; 2021.
30. Patel P, Michael JV, Naik UP, McKenzie SE. Platelet FcγRIIA in immunity and thrombosis: Adaptive immunothrombosis. J Thromb Haemost. 2021;19(5):1149-1160.
31. Rollin J, Pouplard C, Sung HC, et al. Increased risk of thrombosis in FcγRIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2. Blood. 2015;125(15):2397-2404.
32. Amirkhosravi A, Meyer TV, Robles-Carrillo L, et al. β2-Glycoprotein 1 Antibodies Directly Activate the Platelet IgG Receptor, FcγRIIa, and Cause Thrombosis in FCGR2A Transgenic but Not in Wild Type Mice. Blood. 2012;120(21):106.
33. Karnes JH, Shaffer CM, Cronin R, et al.Influence of Human Leukocyte Antigen (HLA) Alleles and Killer Cell Immunoglobulin-Like Receptors (KIR) Types on Heparin-Induced Thrombocytopenia (HIT). Pharmacotherapy. 2017 Sep;37(9):1164-1171
34. Zhang R, Duffy BF, Lange V, Eby CS, Liu C. Association between the HLA-DRB1*03:01-DQB1*02:01 haplotype and PF4/heparin antibodies. Blood Adv. 2019;3(20):3136-3142.
35. Karnes JH, Denny JC, Cronin RM, et al. Abstract 13476: Association of HLA-DRB3*01:01 With Heparin-Induced Thrombocytopenia. Circulation. 2015;132(suppl_3).
36. Yang Y, Du Y, Ivanov D, et al. Molecular architecture and platelet-activating properties of small immune complexes assembled on heparin and platelet factor 4. Communications Biology. 2024;7(1):1-10.
37. Rauova L, Poncz M, McKenzie SE, et al. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood. 2005;105(1):131-138.
38. Datta P, Zhang F, Dordick JS, Linhardt RJ. Platelet factor 4 polyanion immune complexes: heparin induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia. Thromb J. 2021 Sep 15;19(1):66.
39. Sahu KK, Jindal V, Anderson J, Siddiqui AD, Jaiyesimi IA. Current Perspectives on Diagnostic Assays and Anti-PF4 Antibodies for the Diagnosis of Heparin-Induced Thrombocytopenia. J Blood Med. 2020 Aug 17;11:267-277.
40. Levy JH, Hursting MJ. Heparin-induced Thrombocytopenia, a Prothrombotic Disease. Hematol Oncol Clin North Am. 2007;21(1):65-88.
41. Padmanabhan A, Jones CG, Bougie DW, et al. Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis. Blood. 2015;125(1):155-161.
42. Nevzorova TA, Mordakhanova ER, Daminova AG, et al. Platelet factor 4-containing immune complexes induce platelet activation followed by calpain-dependent platelet death. Cell Death Discov. 2019 Jun 24;5:106.
43. Saci A, Pain S, Rendu F, Bachelot-Loza C. Fc Receptor-mediated Platelet Activation Is Dependent on Phosphatidylinositol 3-Kinase Activation and Involves p120. J Biol Chem. 1999;274(4):1898-1904.
44. Chacko GW, Duchemin AM, Coggeshall KM, Osborne JM, Brandt JT, Anderson CL. Clustering of the platelet Fc gamma receptor induces noncovalent association with the tyrosine kinase p72syk. J Biol Chem. 1994 Dec 23;269(51):32435-40.
45. McCrae KR, Shattil SJ, Cines DB. Platelet activation induces increased Fc gamma receptor expression. J Immunol. 1990 May 15;144(10):3920-7.
46. Goldmann L, Duan R, Kragh T, et al. Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT? Blood Adv. 2019 Dec 10;3(23):4021-4033.
47. Perdomo J, Leung HHL, Ahmadi Z, et al. Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia. Nat Commun. 2019;10(1):1322.
48. Perdomo J, Leung HH, Ahmadi Z, Feng Y, Passam FH, Chong BH. Neutrophil Activation and Netosis Are the Key Drivers of Thrombosis in Heparin-Induced Thrombocytopenia. Blood. 2018;132(Supplement 1):378-378.
49. Leung HHL, Perdomo J, Ahmadi Z, Yan F, McKenzie SE, Chong BH. Inhibition of NADPH oxidase blocks NETosis and reduces thrombosis in heparin-induced thrombocytopenia. Blood Adv. 2021;5(23):5439-5451.
50. Gollomp K, Kim M, Johnston I, et al. Neutrophil accumulation and NET release contribute to thrombosis in HIT. JCI Insight. 2018;3(18):e99445.
51. Patel S, Khalil R, Garcia-Bedoya O. Suspected delayed-onset heparin-induced thrombocytopenia from a heparin-bonded PTFE axillofemoral bypass graft. Annals of vascular surgery: Brief reports and innovations. 2023;3(3):100221-100221.
52. Doucette K, DeStefano CB, Jain NA, Cruz AL, Malkovska V, Fitzpatrick K. Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG). Research and Practice in Thromb Haemost. 2017;1(1):134-137.
53. Cuker A, Cines DB. How I treat heparin-induced thrombocytopenia. Blood. 2012;119(10):2209-2218
54. Noorie Pednekar, Sahni R, Brij Ahluwalia-Singh, Thomas A. Delayed Onset Heparin Induced Thrombocytopenia (HIT) Resulting in Common Carotid Artery (CCA) Occlusion (P3.193). Neurology. 2016;86(16_supplement).
55. Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol. 1998 Oct;35(4 Suppl 5):9-16; discussion 35-6.
56. Fathi M. Heparin-induced thrombocytopenia (HIT): Identification and treatment pathways. Global Cardiology Science & Practice. 2018;2018(2).
57. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012;120(20):4160-4167.
58. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006 Apr;4(4):759-65.
59. AL-Mamari A, Al-Farsi K. Clinical presentation and evaluation of the utility of the 4t scoring system in the diagnosis of heparin-induced thrombocytopenia among patients at Sultan Qaboos University Hospital. Hematol Transfus Int J. 2018;6(1).
60. Gardiner EE, Andrews RK, Cuker A. Diagnostic assays for heparin-induced thrombocytopenia. Br J Haematol. 2014;166(5):631-633.
61. Minet V, Dogné JM, Mullier F. Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A Review. Molecules. 2017;22(4):617.
62. Vayne C, Guéry E, Charuel N, et al. Evaluation of functional assays for the diagnosis of heparin-induced thrombocytopenia using 5B9, a monoclonal IgG that mimics human antibodies. J Thromb Haemost. 2020;18(4):968-975.
63. Ahmed I, Majeed A, Powell R. Heparin-induced thrombocytopenia: diagnosis and management update. Postgrad Med J. 2007;83(983):575-582.
64. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med. 1999;106(6):629-635.
65. Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous

thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360-3392.
66. Rougé A, Pelen F, Durand M, Schwebel C. Argatroban for an alternative anticoagulant in HIT during ECMO. J Intensive Care. 2017;5(1).
67. Watson H, Davidson S, Keeling D. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol. 2012;159(5):528-540.
68. Witte JS. Genome-wide association studies and beyond. Annu Rev Public Health. 2010;31:9-20
69. Marees AT, de Kluiver H, Stringer S, Vorspan F, Curis E, Marie-Claire C, Derks EM. A tutorial on conducting genome-wide association studies: Quality control and statistical analysis. Int J Methods Psychiatr Res. 2018 Jun;27(2):e1608.
70. Kwon JM, Goate AM. The candidate gene approach. Alcohol Res Health. 2000;24(3):164-8.
71. Dahlqvist J, Fulco CP, Ray JP, Liechti T, de Boer CG, Lieb DJ, Eisenhaure TM, Engreitz JM, Roederer M, Hacohen N. Systematic identification of genomic elements that regulate FCGR2A expression and harbor variants linked with autoimmune disease. Hum Mol Genet. 2022 Jun 22;31(12):1946-1961.
72. Zhu M, Zhao S. Candidate Gene Identification Approach: Progress and Challenges. Int J Biol Sci. 2007;3(7):420-427.
73. Qin D. Next-generation Sequencing and Its Clinical Application. Cancer Biol Med. 2019;16(1):4-10.
74. Behjati S, Tarpey PS. What is next-generation sequencing? Archives of Disease in Childhood - Education & Practice Edition. 2013;98(6):236-238.
75. Hagenkord J, Funke B, Qian E, et al. Design and Reporting Considerations for Genetic Screening Tests. J Mol Diagn. 2020;22(5):599-609.
76. Burke W. Genetic tests: clinical validity and clinical utility. Curr Protoc Hum Genet. 2014 Apr 24;81:9.15.1-9.15.8.
77. National Academies of Sciences E, Division H and M, Services B on HC, Populations B on the H of S, Testing C on the EB for G. Genetic Test Assessment. National Academies Press (US); 2017. https://www.ncbi.nlm.nih.gov/books/NBK425803/
78. Linkins LA, Dans AL, Moores LK, et al. Treatment and Prevention of Heparin-Induced Thrombocytopenia. Chest. 2012;141(2):e495Se530S.
79. Reich LM, Bower M, Key NS. Role of the geneticist in testing and counseling for inherited thrombophilia. Genet Med. 2003;5(3):133-143.

**How to cite this article**: Haridoss NK, Ravi K. The Role of Genetic Testing in Predicting Response to Heparin and Heparin-Induced Thrombocytopenia. Indian J Pharm Drug Studies 2024; 3(4):137-146.

*Funding: None;* *Conflicts of Interest: None Stated*